Barry S. Taylor, PhD

Associate Member

Barry S. Taylor, PhD

Office Phone


Lab Phone


Dr. Taylor is an Associate Member in the Human Oncology and Pathogenesis Program, Associate Attending Computational Oncologist in the Department of Epidemiology and Biostatistics, and Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology. The goal of his laboratory research is to define the germline and somatic abnormalities that mediate the genesis, progression, and response to therapy of human cancers. His research program lies at the interface of computational and cancer biology, employing translational genomic and functional genetic approaches to identify tumor cell-specific vulnerabilities that can be therapeutically exploited in diverse malignancies. Dr. Taylor’s lab has been involved in many collaborative studies exploring the genomic basic of diverse human cancer types and the development of computational methodologies for cancer genome discovery. His current research centers on exploring the molecular and evolutionary origins of response and resistance to cancer therapy, and defining the mechanisms, serial genetic evolution, and both biological and therapeutic significance of common and rare driver mutations in tumorigenesis. The lab’s overall goal is to capitalize on population-scale and data-driven approaches to accelerate clinical translation in molecularly defined populations of cancer patients.


Selected peer-reviewed publications:

  1. Jonsson P, …, Taylor BS. Tumor lineage shapes BRCA-mediated phenotypes. Nature, 2019; 571 (7766): 576-579. PMID: 31292550.
  2. Bielski CM, …, Taylor BS. Widespread selection for oncogenic mutant allele imbalance in cancer. Cancer Cell, 2018; 34(5): 852-862. PMID:30393068
  3. Razavi P, …, Solit DB†, Taylor BS†, Baselga J†. The genomic landscape of endocrine resistant advanced breast cancers. Cancer Cell, 2018; 34(3): 427-438. PMC6327853
  4. Bielski CM, …, Taylor BS. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet, 2018; 50(8): 1189-1195. PMID: 30013179
  5. Chang MT, …, Taylor BS. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov, 2018; 8(2): 174-183. PMID: 29247016
  6. Yao Z, …, Taylor BS, Rosen N. Tumors with class 3 BRAF mutants are RAS dependent and sensitive to its inhibition. Nature, 2017; 548(7666): 234-238. PMID: 28783719
  7. Hyman DM, …, Taylor BS. AKT inhibition in solid tumors with AKT1 mutations. J Clin Oncol, 2017; 35(20): 2251-2259. PMC5501365
  8. Chang MT, …, Taylor BS. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature Biotechnol. 2016; 34(2): 155-63. PMC4744099
  9. Johnson BE, …, Taylor BS†, Costello JF†. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science, 2014; 343(6167): 189-93. PMC3998672
  10. Iyer G, …, Taylor BS†, Solit DB†. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012; 338(6104): 221. PMC3633467

Visit PubMed for a full listing of Barry S. Taylor’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.